Given a C‑peptide level of 3.44 ng/mL in a patient with fasting glucose 132 mg/dL, elevated fasting insulin, and BMI ≥25 kg/m², is this result normal and how should it guide management?

C-Peptide 3.44 ng/mL is Elevated and Indicates Significant Insulin Resistance

In a patient with fasting glucose 132 mg/dL, elevated fasting insulin, and BMI ≥25 kg/m², a C-peptide level of 3.44 ng/mL is markedly elevated and confirms substantial insulin resistance requiring aggressive metabolic intervention focused on weight reduction, metformin therapy, and cardiovascular risk mitigation.

Understanding the Result in Context

Your C-peptide level of 3.44 ng/mL is approximately 5-6 times higher than what would be considered normal suppression during fasting. According to established guidelines, in healthy individuals with normal glucose metabolism, fasting C-peptide should be below 0.6 ng/mL when plasma glucose drops below 55 mg/dL (3.0 mmol/L) 1, 2. Even at your fasting glucose of 132 mg/dL, this C-peptide level is inappropriately elevated, indicating your pancreatic beta cells are working overtime to overcome severe insulin resistance.

What This Means Clinically

• Insulin hypersecretion is present: Your pancreas is producing excessive amounts of insulin (and C-peptide, its co-secreted marker) in an attempt to maintain glucose control against significant tissue resistance 3
• This is NOT normal: The combination of elevated fasting glucose (132 mg/dL) with markedly elevated C-peptide (3.44 ng/mL) definitively establishes insulin-resistant type 2 diabetes
• Prognostic significance: Higher fasting C-peptide at diabetes diagnosis independently predicts increased all-cause mortality and cancer-related mortality, even after adjusting for other risk factors 4

Critical Management Priorities

1. Address Insulin Resistance Aggressively

Weight reduction is paramount. Research specifically in non-obese Asian Indians (BMI 19-25 kg/m²) with elevated C-peptide demonstrated that intra-abdominal adipose tissue (IAAT) volume and liver span were independent predictors of elevated fasting C-peptide 3. Even with BMI ≥25 kg/m², visceral fat accumulation drives this pathophysiology.

Target interventions:

• Aim for 7-10% body weight reduction through caloric restriction
• Focus on reducing visceral adiposity specifically (not just total weight)
• Implement structured exercise program (150+ minutes weekly moderate-intensity activity)

2. Pharmacologic Therapy

Metformin should be initiated immediately if not already prescribed. Your metabolic profile (elevated C-peptide indicating insulin resistance, impaired fasting glucose, BMI ≥25) represents the classic indication for metformin as first-line therapy.

Consider adding:

• GLP-1 receptor agonists for dual benefit of glucose control and weight reduction
• SGLT2 inhibitors for cardiovascular and renal protection, particularly given the mortality risk associated with elevated C-peptide 4

3. Cardiovascular Risk Assessment

The elevated C-peptide level signals heightened cardiovascular risk independent of glucose control. You must aggressively manage:

• Blood pressure (target <130/80 mmHg)
• LDL cholesterol (consider statin therapy if not contraindicated)
• Screen for and treat fatty liver disease (strongly associated with elevated C-peptide 3)

4. Monitor for Beta Cell Exhaustion

While your C-peptide is currently elevated, this represents a compensatory phase. Over time, beta cells may fail under this excessive secretory burden. Serial monitoring is essential:

• Repeat C-peptide and glucose measurements every 6-12 months
• Declining C-peptide over time (while glucose rises) signals beta cell failure requiring insulin therapy
• HbA1c monitoring every 3 months initially

Important Caveats

Laboratory validation matters: The thresholds cited (C-peptide <0.6 ng/mL for hypoglycemia diagnosis) were validated using specific assay methods (ICMA, notably ADVIA Centaur kit) 2. Ensure your laboratory uses comparable methodology, though the magnitude of your elevation (3.44 ng/mL) makes assay variation clinically irrelevant.

Renal function consideration: These C-peptide thresholds were established in patients without renal insufficiency 2. If you have kidney disease, C-peptide interpretation becomes more complex as clearance is impaired.

This is NOT insulinoma: Some might worry about elevated C-peptide, but insulinoma presents with C-peptide ≥0.6 ng/mL during hypoglycemia (glucose <55 mg/dL), not during hyperglycemia 1, 2. Your elevated glucose excludes this diagnosis entirely.

Bottom Line Algorithm

1. Confirm diagnosis: Type 2 diabetes with severe insulin resistance (based on C-peptide 3.44 ng/mL + fasting glucose 132 mg/dL + BMI ≥25)
2. Initiate metformin (if not already prescribed)
3. Implement intensive lifestyle modification targeting 7-10% weight loss
4. Screen for metabolic complications: fatty liver (ultrasound/elastography), cardiovascular disease (lipid panel, blood pressure), diabetic retinopathy and nephropathy
5. Consider additional glucose-lowering agents with cardiovascular benefit (GLP-1 RA or SGLT2i)
6. Monitor C-peptide trajectory every 6-12 months to detect beta cell decline

The research evidence consistently demonstrates that elevated fasting C-peptide at diagnosis carries independent prognostic significance for mortality 4, making aggressive intervention imperative rather than optional.